Acurx Pharmaceuticals ACXP
NASDAQ ACXP
$1.18 +0.03 (+2.61%)
As of: Oct 22, 2026 · 10:55 AM EDT

Acurx Pharmaceuticals (ACXP) Return on Assets [ROA] (2025 - 2026)

Updated

Acurx Pharmaceuticals' Return on Assets [ROA] was -73.14% in Q2 2026, up 109.26 percentage points from -182.41% a year earlier and up 13.90 percentage points from the prior quarter.

Analysis

Acurx Pharmaceuticals (ACXP) Return on Assets [ROA] (2025 - 2026) Analysis & Trends

For FY2025, Return on Assets [ROA] at Acurx Pharmaceuticals came in at -137.98%, up 105.87 percentage points from FY2024.

  • In earlier years, Return on Assets [ROA] was -243.85% in FY2024.
  • Per Business Quant data, ACXP's Return on Assets [ROA] in the three quarters before Q2 2026 was -87.04% (Q1 2026), -115.50% (Q4 2025) and -149.56% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,172.05 Bn 1,140.63 Bn 19.71 Bn 20.64%
2 Johnson & Johnson 636.25 Bn 554.77 Bn 17.26 Bn 10.47%
3 AbbVie 503.38 Bn 476.49 Bn 12.70 Bn 4.65%
4 Merck 377.92 Bn 332.30 Bn 12.21 Bn 2.45%
5 Novartis Ag 304.19 Bn 268.18 Bn 11.24 Bn 10.60%
6 Astrazeneca 267.24 Bn 240.93 Bn 12.86 Bn 9.10%
7 Amgen 242.06 Bn 197.46 Bn 7.24 Bn 9.29%
8 Gilead Sciences 193.78 Bn 167.97 Bn 6.22 Bn -6.13%
9 Pfizer 172.54 Bn 119.18 Bn 10.94 Bn 2.14%
10 Acurx Pharmaceuticals 5.03 Mn -28.44 Mn - -73.14%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -73.14%
Mar 31, 2026 -87.04%
Dec 31, 2025 -115.50%
Sep 30, 2025 -149.56%
Jun 30, 2025 -182.41%
Mar 31, 2025 -274.13%
API Access

Acurx Pharmaceuticals Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=ACXP&period=max&api_key=YOUR_API_KEY